Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of Catch-up Vaccination Regimens of V114 (V114-024)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria~* Not be pregnant or breastfeeding~* Not be a woman of childbearing potential~* If of a woman of childbearing potential, agree to follow the contraceptive guidance during the treatment period and for at least 6 weeks after the last dose of study intervention~* Has a legally acceptable representative who understands the study procedures, alternate treatments available, and risks involved with the study and voluntarily agrees to participate by giving written informed consent~Exclusion Criteria~* History of invasive pneumococcal disease (IPD)~* Known hypersensitivity to any component of the PCV or any diphtheria toxoid-containing vaccine~* Had a recent febrile illness occurring within 72 hours prior to receipt of study vaccine~* Known or suspected impairment of immunological function~* History of congenital or acquired immunodeficiency~* Has or his/her mother has a documented human immunodeficiency virus (HIV) infection~* Known or history of functional or anatomic asplenia~* Has failure to thrive based on the clinical judgement of the investigator~* Has a bleeding disorder contraindicating intramuscular vaccination~* Has a history of autoimmune disease (including but not limited to systemic lupus erythematosus, antiphospholipid syndrome, Behcet's disease, autoimmune thyroid disease, polymyositis and dermatomyositis, scleroderma, type 1 diabetes mellitus, or other autoimmune disorders)~* Has known neurologic or cognitive behavioral disorder, including encephalitis/myelitis, acute disseminating encephalomyelitis, pervasive development disorder, and related disorders~* Is 7 to 23 months of age and has received a dose of a pneumococcal vaccine prior to study entry based on medical record. Participants ≥2 years of age could have received a PCV at least 8 weeks prior to study entry as follows: a partial regimen of Prevnar™,Synflorix™, or Prevnar 13™ or a full regimen of Prevnar™ or Synflorix™ based on local guidelines. Participants should not have received any dose of a pneumococcal polysaccharide vaccine~* Meets one or more of the following systemic corticosteroid exclusion criteria: has received systemic corticosteroids (equivalent of ≥2 mg/kg total daily dose of prednisone or ≥20 mg/day for persons weighing \>10 kg) for ≥14 consecutive days and has not completed this course of treatment at least 30 days prior to the first dose of study vaccine at randomization; has received or is expected to receive systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days prior to any dose of study vaccine; or is expected to require systemic corticosteroids within 30 days after any study vaccination during conduct of the study (Note: Topical, ophthalmic and inhaled steroids are permitted)~* Has received other licensed non-live vaccines within 14 days before receipt of study vaccine. Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of study vaccine or at least 15 days after receipt of study vaccine~* Has received a licensed live vaccine within 30 days before receipt of study vaccine~* Has received a blood transfusion or blood products, including immunoglobulins, within 6 months before receipt of study vaccine~* Has participated in another clinical study of an investigational product before the beginning or anytime during the duration of the current clinical study

- Gender: ALL
- Minimum Age: 7 Months
- Maximum Age: 17 Years
- Healthy Volunteers: t

Study Arms:
- V114, Schedule A: Participants 7-11 months (Type: EXPERIMENTAL): Each participant received a 0.5 mL intramuscular (IM) injection for 7 to 11 months of age (Pneumococcal conjugate vaccine \[PCV\]-naïve)(3 doses). Dose 1: at randomization, Dose 2: 4 to 8 weeks after Dose 1, and Dose 3: 8 to 12 weeks after Dose 2 and ≥12 months of age.
- Prevnar 13®, Schedule A: Participants 7-11 months (Type: ACTIVE_COMPARATOR): Each participant received a 0.5 mL IM injection for 7 to 11 months of age (PCV-naïve)(3 doses). Dose 1: at randomization, Dose 2: 4 to 8 weeks after Dose 1, and Dose 3: 8 to 12 weeks after Dose 2 and ≥12 months of age.
- V114, Schedule B: Participants 12-23 months (Type: EXPERIMENTAL): Each participant received a 0.5 mL IM injection for 12 to 23 months of age (PCV-naïve)(2 doses). Dose 1: at randomization, and Dose 2: 8 to 12 weeks after Dose 1.
- Prevnar 13®, Schedule B: Participants 12-23 months (Type: ACTIVE_COMPARATOR): Each participant received a 0.5 mL IM injection for 12 to 23 months of age (PCV-naïve)(2 doses). Dose 1: at randomization, and Dose 2: 8 to 12 weeks after Dose 1.
- V114, Schedule C: Participants 2-17 years (Type: EXPERIMENTAL): Each participant received a 0.5 mL IM injection for 2 to 17 years of age (PCV-naïve or PCV-experienced) (1 dose). Single dose administered at randomization and at least 8 weeks after previous PCV for participants who were PCV-experienced.
- Prevnar 13®, Schedule C: Participants 2-17 years (Type: ACTIVE_COMPARATOR): Each participant received a 0.5 mL IM injection for 2 to 17 years of age (PCV-naïve or PCV-experienced)(1 dose). Single dose administered at randomization and at least 8 weeks after previous PCV for participants who were PCV-experienced.

Based on this trial design, predict the completion outcome and termination type (if applicable).